SINGAPORE — Samsung BioLogics was flying high at the big J.P. Morgan biotech investment conference in San Francisco last month.
The company had recently spent the equivalent of $740 million to build its third huge biosimilar plant in the biopharma hub of Songdo, South Korea. And the shiny new facility was attracting big name clients, including Bristol-Myers Squibb and Roche.
